Retina: a unique subspecialty in the biosimilar landscape

[1]  C. Regillo,et al.  Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam’s Razor? , 2021, Ocular immunology and inflammation.

[2]  R. Narayanan,et al.  Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey , 2021, Indian journal of ophthalmology.

[3]  A. Loewenstein,et al.  Biosimilars for Retinal Diseases: An Update. , 2020, American journal of ophthalmology.

[4]  P. Mitchell,et al.  Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems , 2020, BMC Ophthalmology.

[5]  A. Loewenstein,et al.  Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect , 2019, Eye.

[6]  A. Loewenstein,et al.  Biosimilars in ophthalmology: “Is there a big change on the horizon?” , 2018, Clinical ophthalmology.

[7]  Atul Kumar,et al.  Using intravitreal bevacizumab (Avastin®) – Indian Scenario , 2017, Indian journal of ophthalmology.

[8]  K. Petrie,et al.  Medical specialists' attitudes to prescribing biosimilars , 2017, Pharmacoepidemiology and drug safety.

[9]  P. Mondal,et al.  Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial , 2016, Indian journal of ophthalmology.

[10]  FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss , 2022 .

[11]  U. Schmidt-Erfurth,et al.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology.

[12]  D. Yorston.  Anti-VEGF drugs in the prevention of blindness , 2014, Community eye health.